SCHEMBL4348902

SCHEMBL4348902

Cc1ccccc1CNC(=O)Nc1cc(Cl)cc(C(C)O)c1O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.55
RAB9A P51151 3/20 0.55
ALDH1A1 P00352 2/20 0.46
MEN1 O00255 1/20 0.46
GAA P10253 1/20 0.46
PKM P14618 1/20 0.46
KMT2A Q03164 1/20 0.46
HPGD P15428 2/20 0.40
LMNA P02545 1/20 0.40
PPARG P37231 1/20 0.40
SCN2A Q99250 1/20 0.40
SCN10A Q9Y5Y9 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C19 P33261 1/20 0.40
NAMPT P43490 1/20 0.39
ROCK2 O75116 1/20 0.39
ROCK1 Q13464 1/20 0.39
MARS1 P56192 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4347975 0.87 ALOX12 (0.51) NPC1RAB9AALDH1A1MEN1KMT2A
SCHEMBL4342033 0.85 RAB9A (0.61) NPC1RAB9AALDH1A1MEN1GAA
SCHEMBL4351678 0.83 DDX3X (0.49) NPC1RAB9AALDH1A1MEN1GAA
SCHEMBL4354116 0.82 NPC1 (0.58) NPC1RAB9AALDH1A1MEN1GAA
SCHEMBL4351118 0.80 CXCL8 (0.44) RAB9AMEN1PKMKMT2ALMNA
SCHEMBL4347982 0.80 NPC1 (0.41) NPC1RAB9AALDH1A1GAAKMT2A
SCHEMBL4349972 0.79 RAB9A (0.66) NPC1RAB9AALDH1A1MEN1GAA
SCHEMBL4353910 0.79 CNR1 (0.52) NPC1RAB9AALDH1A1MEN1KMT2A
SCHEMBL12846741 0.78 NPC1 (0.69) NPC1RAB9AALDH1A1MEN1GAA
SCHEMBL4342004 0.77 KMT2A (0.54) NPC1RAB9AMEN1GAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
CN-100546977-C Suppress the new compound and the application thereof of rotamase JERINI AG (DE) 2009-10-07 CN claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 NPC1 815/4885RAB9A 4228/4885ALDH1A1 2565/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 NPC1 1189/4885RAB9A 4588/4885ALDH1A1 2767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.